CTIS2023-505434-98-00进行中（未招募）1 期
RNPK1018
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Study of RP2 alone and in combination with PD1 Blockade in patients with solid tumoursSolid tumorsMedDRA version: 21.0Level: LLTClassification code: 10049280Term: Solid tumour Class: 10029104CTIS2024-512866-32-00Replimune Group Inc.86
进行中（未招募）
1 期
A Multiple-Ascending-Dose Study of MK-4318 in Healthy ParticipantsPainMedDRA version: 20.1Level: LLTClassification code: 10049475Term: Chronic pain Class: 10018065MedDRA version: 20.1Level: LLTClassification code: 10066714Term: Acute pain Class: 10018065CTIS2023-507512-12-00Merck Sharp & Dohme LLC32
进行中（未招募）
1 期
Phase I, double-blind, randomized, placebo-controlled study investigating the safety, tolerability and concentrations of the study product KAND145 in healthy volunteersMedDRA version: 20.0Level: PTClassification code: 10033128Term: Ovarian cancer Class: 100000004864Ovarian cancerCTIS2023-503909-11-00Kancera AB80
进行中（未招募）
1 期
Imatinib PD in healthy subjectsImmuno-oncology assessmentsCTIS2023-504958-35-00Centre for Human Drug Research36
进行中（未招募）
1 期
A Phase 1 Study Evaluating Relative Bioavailability of Sprinkled Ritlecitinib in Applesauce, Yoghurt, and Strawberry Jam and Evaluating the Effect of Food on the Bioavailability of Ritlecitinib Intact Blend-In Capsule in Healthy Adult Participants.Alopecia Areata, Rheumatoid Arthritis, Vitiligo, Ulcerative Colitis and Crohn's DiseaseMedDRA version: 21.1Level: PTClassification code: 10047642Term: Vitiligo Class: 100000004858MedDRA version: 21.0Level: PTClassification code: 10039073Term: Rheumatoid arthritis Class: 100000004859MedDRA version: 20.1Level: LLTClassification code: 10045365Term: Ulcerative colitis Class: 10017947MedDRA version: 20.0Level: PTClassification code: 10001761Term: Alopecia areata Class: 100000004858MedDRA version: 20.0Level: PTClassification code: 10011401Term: Crohn's disease Class: 100000004856CTIS2022-502872-22-00Pfizer Inc.12